Cell-based therapies are rewriting the rules of modern medicine. Stem cells — embryonic, adult, or induced pluripotent — now power some of the most promising clinical pipelines in oncology, regenerative medicine, and rare diseases. But these are not classical drugs. They are living, dividing, evolving products whose genetic stability is never guaranteed.
This raises a fundamental question that pharmaceutical toxicology has only recently begun to address: how do you assess the genotoxic risk of a product whose biology continues to change after it leaves the laboratory?
Classical genotoxicity testing was designed for small molecules. It tells us little about the genomic drift of a stem cell line through reprogramming, expansion, or gene editing. As Advanced Therapy Medicinal Products (ATMPs) move from research benches to industrial pipelines, regulators, sponsors, and CROs are converging on a new principle: stem cell quality control must be product-specific, lot-specific, and continuous.
This article offers a scientific and regulatory overview of the genotoxic risks associated with stem cell-based products — and the quality control strategies that can secure their development.
What are stem cells, and why do they matter in modern medicine?
Embryonic, adult, induced pluripotent (iPSC) — a quick overview
Stem cells are defined by two core properties: self-renewal and differentiation potential. Three main categories dominate today’s research and clinical landscape:
- Embryonic stem cells (ESCs) — pluripotent cells derived from the inner cell mass of the blastocyst. Powerful, but ethically and regulatorily constrained.
- Adult stem cells, including mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) — multipotent cells found in bone marrow, adipose tissue, umbilical cord, and several adult tissues.
- Induced pluripotent stem cells (iPSCs) — somatic cells reprogrammed to a pluripotent state, typically using transcription factors such as OCT4, SOX2, KLF4 and c-MYC. Since their discovery by Yamanaka in 2006, iPSCs have become the workhorse of personalised regenerative medicine.
Each category brings distinct biological capabilities — and distinct genotoxic risk profiles.
Therapeutic applications: ATMPs, regenerative medicine, CAR-T, MSC therapies
Stem cells now sit at the heart of Advanced Therapy Medicinal Products (ATMPs), a regulatory category that includes gene therapies, somatic cell therapies, and tissue-engineered products. Concrete applications include:
- Regenerative medicine — repairing cardiac tissue post-infarction, restoring beta-cell function in diabetes, treating macular degeneration with iPSC-derived retinal cells.
- Oncology — CAR-T cell therapies (although derived from T cells, they share many quality challenges with stem cell products).
- MSC-based therapies — graft-versus-host disease, autoimmune disorders, orthopaedic regeneration.
- iPSC-derived models — disease modelling, drug screening, and increasingly, allogeneic “off-the-shelf” therapies.
Behind each of these promises lies the same scientific imperative: proving that the cells administered to a patient are genomically safe.
The genotoxic risk profile of stem cell-based products
Genomic instability during reprogramming and expansion
Every step in stem cell manufacturing is a potential genotoxic event. Reprogramming somatic cells into iPSCs involves massive epigenetic remodelling and replicative stress, which can trigger DNA damage and mutations. Long-term expansion in vitro — necessary to obtain clinical-grade quantities — selects for cells that proliferate fastest, sometimes those carrying advantageous (and dangerous) genomic alterations.
The longer a stem cell line is cultured, the more its genome drifts from its starting state. This is not a theoretical concern: recurrent chromosomal abnormalities are well documented in iPSC and ESC lines worldwide.
Chromosomal aberrations, aneuploidy, copy number variations
Three categories of genomic alterations are routinely observed in stem cell-based products:
- Aneuploidies — gain or loss of entire chromosomes, with chromosome 12 trisomy being a recurrent finding in pluripotent lines.
- Sub-karyotypic alterations — duplications such as the well-known 20q11.21 amplification, associated with resistance to apoptosis and increased tumorigenic potential.
- Copy number variations (CNVs) and single-nucleotide variants (SNVs) — often invisible to standard karyotyping but detectable through array-CGH or next-generation sequencing.
Some of these alterations are silent. Others affect tumour suppressor genes, oncogenes, or DNA repair pathways. The challenge is no longer detecting them — it is interpreting their clinical significance.
Risk of tumorigenicity and insertional mutagenesis
When stem cells are genetically modified — for instance through lentiviral vectors or CRISPR/Cas9 editing — a second layer of genotoxic risk emerges:
- Insertional mutagenesis — random integration of viral vectors near oncogenes, a risk historically illustrated by early gene therapy trials.
- Off-target editing — unintended cuts and rearrangements caused by gene-editing nucleases.
- Tumorigenicity — the residual presence of undifferentiated, proliferative cells in the final product, capable of forming teratomas after administration.
These risks are not hypothetical. They are explicitly addressed by regulatory authorities — and they require purpose-built quality control strategies.
Why classical genotoxicity testing is not enough
Limits of Ames, in vitro micronucleus and chromosomal aberration assays for living cells
The standard genotoxicity battery Ames test, in vitro micronucleus assay, chromosomal aberration test, was developed and validated for chemical entities: small molecules with predictable chemistry and stable structure. Stem cell-based products break that paradigm.
A few practical limits:
- The Ames test uses bacterial strains. It cannot evaluate the genomic stability of human cells.
- The classical in vitro micronucleus assay is performed on standardised cell lines (CHO, TK6…), not on the actual therapeutic product.
- Chromosomal aberration testing detects gross structural abnormalities but misses sub-karyotypic alterations, CNVs and gene-level events.
These assays remain essential — for instance to test ancillary materials, culture media components, or impurities. But they cannot, on their own, certify the genomic safety of a cell therapy product.
The need for product-specific, lot-specific quality controls
Cell therapies are inherently heterogeneous. Two lots from the same donor, processed under the same protocol, may diverge genomically. Two passages of the same iPSC line may carry different aberrations.
This biological reality forces a paradigm shift: from substance-level to batch-level quality control. Every lot must be characterised. Every clinically relevant passage must be documented. Every release must be supported by genomic evidence.
The toolbox required for this is broader, more sensitive, and more interpretive than what classical genotoxicity testing offers.
Regulatory framework: what EMA, FDA and ICH expect
ICH Q5A(R2), ICH Q5D, ICH S6(R1) — what applies to cell therapies
Several ICH guidelines structure the regulatory expectations for stem cell-based products:
- ICH Q5A(R2) — viral safety of biotechnology products derived from cell lines, recently updated to address advanced therapies.
- ICH Q5D — quality of biotechnological/biological products: characterisation of cell substrates used for production.
- ICH S6(R1) — preclinical safety evaluation of biotechnology-derived pharmaceuticals, often used as a reference framework for ATMP safety strategies.
While none of these texts is fully tailored to stem cell therapies, they provide the regulatory backbone on which cell therapy developers must build their quality programmes.
EMA Guideline on quality of ATMPs / FDA CBER expectations
In Europe, the EMA Committee for Advanced Therapies (CAT) has issued specific guidelines covering quality, non-clinical, and clinical aspects of ATMPs, including dedicated guidance on genetically modified cells. In the United States, FDA CBER publishes detailed expectations for cellular and gene therapy products.
Across both regions, three principles converge:
- Genomic stability must be demonstrated at multiple stages — master cell bank, working cell bank, end-of-production cells.
- Tumorigenicity assessment is expected for pluripotent-derived products.
- Integration site analysis is required for genetically modified cell therapies.
The role of GLP and ISO 17025 in ATMP quality assurance
Generating regulatory-grade data requires more than scientific expertise. It requires certified quality systems: Good Laboratory Practice (GLP) for safety studies, ISO 17025 for testing laboratories, and increasingly ISO 10993 when biocompatibility intersects with cell therapies.
A CRO holding both GLP and ISO 17025 — a rare combination in Europe — can deliver data that is both scientifically robust and regulatory-ready, reducing the risk of dossier rejection or additional studies during the clinical trial application.
Quality control toolbox for stem cell-based products
Karyotyping & FISH (telomere/centromere)
Conventional karyotyping remains a baseline test for detecting numerical and gross structural chromosomal abnormalities. But it lacks resolution for sub-karyotypic events.
FISH (Fluorescence In Situ Hybridisation), and particularly Telomere & Centromere FISH (T&C FISH), brings dramatic improvements: telomere shortening, centromeric loss, and chromosomal mis-segregation can be visualised at single-cell level. This high-resolution approach is especially valuable for monitoring chromosomal instability (CIN) in expanded cell lines.
GenEvolutioN is, to our knowledge, the only private CRO laboratory in France offering Telomere & Centromere FISH staining within a GLP-compliant micronucleus assay framework — a differentiating capability for ATMP developers seeking high-resolution genomic surveillance.
Micronucleus assay adapted to stem cell lines
The in vitro micronucleus assay — historically a regulatory cornerstone — can be adapted to stem cell biology. Performed on the actual therapeutic cells (or a representative model), coupled with T&C FISH and modern image analysis, it becomes a powerful tool for detecting both clastogenic (chromosome-breaking) and aneugenic (chromosome-loss) events specific to the product.
Next-generation approaches: NAMs, deep learning, biomarkers
The future of stem cell quality control belongs to New Approach Methodologies (NAMs):
- gH2AX and pH3 biomarkers — early indicators of DNA damage and mitotic stress, allowing genotoxic events to be detected before they translate into structural aberrations.
- Deep-learning image analysis — automating micronucleus scoring and chromosomal anomaly detection with reproducibility well beyond manual reading.
- Single-cell and array-based genomics — moving from population-level to cell-level resolution.
These technologies are no longer experimental. They are gradually entering regulatory dossiers and shaping the future of ATMP safety assessment.
How GenEvolutioN supports cell therapy developers
GenEvolutioN brings together a 50-year scientific heritage rooted in Sanofi’s preclinical legacy with one of the most complete genotoxicity portfolios in Europe: Ames test, micronucleus assay, in vitro chromosomal aberration testing, gH2AX/pH3 biomarkers, and Telomere & Centromere FISH.
Our dual GLP and ISO 17025 accreditation, combined with ISO 10993 capabilities, allows us to support cell therapy developers across the full quality continuum — from early R&D to regulatory submission. Our partnership with AsedaSciences (3RnD platform) further extends our reach into next-generation in vitro safety profiling.
For ATMP sponsors, this means a single scientific partner capable of designing genotoxicity strategies that meet both EMA and FDA expectations — and ready to evolve as the regulatory framework matures.
Stem cell therapies are redefining what medicine can achieve. They are also redefining what toxicology and quality control must deliver. Genomic instability, tumorigenicity, and insertional mutagenesis are no longer edge cases — they are central concerns of every ATMP development programme.
The path forward is clear: combine the proven rigour of classical genotoxicity testing with product-specific assays, high-resolution genomic tools, and next-generation methodologies. And do it within a quality framework that regulators recognise.
👉 Discuss your ATMP genotoxicity strategy with our experts — Contact GenEvolutioN
